Plasmin treatment accelerates vascular endothelial growth factor clearance from rabbit eyes

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 9, 2011, Pages 6162-6167

  Wu, Wei Chi ^a,b   Chen, Chih Chun ^a   Liu, Chi Hsien ^c   Wang, Nan Kai ^a,b   Chen, Kuan Jen ^a,b   Chen, Tun Lu ^a,b   Hwang, Yih Shiou ^a,b   Li, Lien Min ^a   Lai, Chi Chun ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMIN; SULFUR HEXAFLUORIDE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; NONHUMAN; PRIORITY JOURNAL; RABBIT; VITREOUS BODY; VITREOUS BODY DETACHMENT;

ANIMALS; DRUG COMBINATIONS; ELECTRORETINOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIN; INTRAVITREAL INJECTIONS; MICROSCOPY, ELECTRON, SCANNING; RABBITS; SULFUR HEXAFLUORIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY; VITREOUS DETACHMENT;

EID: 80051490324     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6396     Document Type: Article

References (66)

1. Wirostko B, Wong TY, Simo R. Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res. 2008;27:608-621.
2. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1: 1024-1028.
3. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111:707-716.
4. Raab S, Plate KH. Different networks, common growth factors: shared growth factors and receptors of the vascular and the nervous system. Acta Neuropathol. 2007;113:607-626.
5. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995;113:1538-1544.
6. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 1999;14:223-232.
7. Sato T, Kusaka S, Shimojo H, Fujikado T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology. 2009;116:2165-2169.
8. Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology. 2009;116:1599-1603.
9. Pe'er J, Folberg R, Itin A, et al. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol. 1996;80:241-245.
10. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
11. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1-29.
12. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol. 2002;120:1644-1650.
13. Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005;140:256-261.
14. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
15. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695-1705.
16. Cao J, Zhao L, Li Y, et al. A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap. Invest Ophthalmol Vis Sci. 2010;51:6009-6017.
17. Greenberger S, Boscolo E, Adini I, et al. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med. 2010;362:1005-1013.
18. Liotta LA, Goldfarb RH, Brundage R, et al. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 1981;41:4629-4636.
19. Russell SR, Shepherd JD, Hageman GS. Distribution of glycoconjugates in the human retinal internal limiting membrane. Invest Ophthalmol Vis Sci. 1991;32:1986-1995.
20. Kohno T, Sorgente N, Ishibashi T, et al. Immunofluorescent studies of fibronectin and laminin in the human eye. Invest Ophthalmol Vis Sci. 1987;28:506-514.
21. Diaz-Llopis M, Udaondo P, Arevalo F, et al. Intravitreal plasmin without associated vitrectomy as a treatment for refractory diabetic macular edema. J Ocul Pharmacol Ther. 2009;25:379-384.
22. Trese MT, Williams GA, Hartzer MK. A new approach to stage 3 macular holes. Ophthalmology. 2000;107:1607-1611.
23. Tsukahara Y, Honda S, Imai H, et al. Autologous plasmin-assisted vitrectomy for stage 5 retinopathy of prematurity: a preliminary trial. Am J Ophthalmol. 2007;144:139-141.
24. Williams JG, Trese MT, Williams GA, Hartzer MK. Autologous plasmin enzyme in the surgical management of diabetic retinopathy. Ophthalmology. 2001;108:1902-1905.
25. Wu WC, Drenser KA, Lai M, et al. Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity. Retina. 2008;28:S75-S80.
26. Wu WC, Drenser KA, Capone A, et al. Plasmin enzyme-assisted vitreoretinal surgery in congenital X-linked retinoschisis: surgical techniques based on a new classification system. Retina. 2007;27: 1079-1085.
27. Wu WC, Drenser KA, Trese MT, et al. Pediatric traumatic macular hole: results of autologous plasmin enzyme-assisted vitrectomy. Am J Ophthalmol. 2007;144:668-672.
28. Sebag J, Ansari RR, Suh KI. Pharmacologic vitreolysis with microplasmin increases vitreous diffusion coefficients. Graefes Arch Clin Exp Ophthalmol. 2007;245:576-580.
29. Quiram PA, Leverenz VR, Baker RM, et al. Microplasmin-induced posterior vitreous detachment affects vitreous oxygen levels. Retina. 2007;27:1090-1096.
30. Goldenberg DT, Trese MT. Pharmacologic vitreodynamics and molecular flux. Dev Ophthalmol. 2009;44:31-36.
31. Hikichi T, Yanagiya N, Kado M, et al. Posterior vitreous detachment induced by injection of plasmin and sulfur hexafluoride in the rabbit vitreous. Retina. 1999;19:55-58.
32. Gandorfer A, Rohleder M, Sethi C, et al. Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci. 2004; 45:641-647.
33. Cornea and Contact Lenses Research Unit. CCLRU grading scales. Sydney, Australia: University of New South Wales; 1996.
34. Dano K, Andreasen PA, Grondahl-Hansen J, et al. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985; 44:139-266.
35. Ghajar CM, Kachgal S, Kniazeva E, et al. Mesenchymal cells stimulate capillary morphogenesis via distinct proteolytic mechanisms. Exp Cell Res. 2010;316:813-825.
36. Okajima K, Abe H, Binder BR. Endothelial cell injury induced by plasmin in vitro. J Lab Clin Med. 1995;126:377-384.
37. Hikichi T, Konno S, Trempe CL. Role of the vitreous in central retinal vein occlusion. Retina. 1995;15:29-33.
38. Joshi MM, Ciaccia S, Trese MT, Capone A Jr. Posterior hyaloid contracture in pediatric vitreoretinopathies. Retina. 2006;26:S38-S41.
39. Nasrallah FP, Jalkh AE, Van Coppenolle F, et al. The role of the vitreous in diabetic macular edema. Ophthalmology. 1988;95: 1335-1339.
40. Robison CD, Krebs I, Binder S, et al. Vitreomacular adhesion in active and end-stage age-related macular degeneration. Am J Ophthalmol. 2009;148:79-82.
41. Tagawa H, McMeel JW, Furukawa H, et al. Role of the vitreous in diabetic retinopathy. I. Vitreous changes in diabetic retinopathy and in physiologic aging. Ophthalmology. 1986;93:596-601.
42. Machemer R. Description and pathogenesis of late stages of retinopathy of prematurity. Ophthalmology. 1985;92:1000-1004.
43. Schepens CL, Avila MP, Jalkh AE, Trempe CL. Role of the vitreous in cystoid macular edema. Surv Ophthalmol. 1984;28 Suppl:499-504.
44. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
45. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelvemonth safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246:81-87.
46. Hirata A, Takano A, Inomata Y, et al. Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: a pilot study. Retina. 2007;27:1074-1078.
47. Rizzo S, Pellegrini G, Benocci F, et al. Autologous plasmin for pharmacologic vitreolysis prepared 1 hour before surgery. Retina. 2006;26:792-796.
48. de Smet MD, Gandorfer A, Stalmans P, et al. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology. 2009; 116:1349-1355.
49. Azzolini C, D'Angelo A, Maestranzi G, et al. Intrasurgical plasmin enzyme in diabetic macular edema. Am J Ophthalmol. 2004;138: 560-566.
50. Asami T, Terasaki H, Kachi S, et al. Ultrastructure of internal limiting membrane removed during plasmin-assisted vitrectomy from eyes with diabetic macular edema. Ophthalmology. 2004; 111:231-237.
51. Russell SR, Hageman GS. Optic disc, foveal, and extrafoveal damage due to surgical separation of the vitreous. Arch Ophthalmol. 2001;119:1653-1658.
52. Gandorfer A, Putz E, Welge-Lussen U, et al. Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy. Br J Ophthalmol. 2001;85:6-10.
53. Benz MS, Packo KH, Gonzalez V, et al. A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy. Ophthalmology. 2010;117:791-797.
54. He L, Niemeyer B. A novel correlation for protein diffusion coefficients based on molecular weight and radius of gyration. Biotechnol Prog. 2003;19:544-548.
55. Nishimura Y, Hayashi H, Oshima K, Iwata S. [Alteration of diffusion velocity of fluorescein-Na in dependence on vitreous liquefaction]. Nippon Ganka Gakkai Zasshi. 1986;90:1313-1316.
56. Xu J, Heys JJ, Barocas VH, Randolph TW. Permeability and diffusion in vitreous humor: implications for drug delivery. Pharm Res. 2000;17:664-669.
57. Stefanini MO, Wu FT, Mac GF, Popel AS. A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst Biol. 2008;2:77.
58. Ponsioen TL, van Luyn MJ, van der Worp RJ, et al. Collagen distribution in the human vitreoretinal interface. Invest Ophthalmol Vis Sci. 2008;49:4089-4095.
59. Verstraeten TC, Chapman C, Hartzer M, et al. Pharmacologic induction of posterior vitreous detachment in the rabbit. Arch Ophthalmol. 1993;111:849-854.
60. de Smet MD, Valmaggia C, Zarranz-Ventura J, Willekens B. Microplasmin: ex vivo characterization of its activity in porcine vitreous. Invest Ophthalmol Vis Sci. 2009;50:814-819.
61. Foos RY. Vitreoretinal juncture: topographical variations. Invest Ophthalmol. 1972;11:801-808.
62. Gloor BP, Daicker BC. Pathology of the vitreo-retinal border structures. Trans Ophthalmol Soc U K. 1975;95:387-390.
63. Malecaze F, Caratero C, Caratero A, et al. Some ultrastructural aspects of the vitreoretinal juncture. Ophthalmologica. 1985;191: 22-28.
64. Kim NJ, Yu HG, Yu YS, Chung H. Long-term effect of plasmin on the vitreolysis in rabbit eyes. Korean J Ophthalmol. 2004;18: 35-40.
65. Wang F, Wang Z, Sun X, et al. Safety and efficacy of dispase and plasmin in pharmacologic vitreolysis. Invest Ophthalmol Vis Sci. 2004;45:3286-3290.
66. Margherio AR, Margherio RR, Hartzer M, et al. Plasmin enzymeassisted vitrectomy in traumatic pediatric macular holes. Ophthalmology. 1998;105:1617-1620.